Head to Head Survey: Hypertension Diagnostics (OTCMKTS:HDII) and NeuroPace (NASDAQ:NPCE)

NeuroPace (NASDAQ:NPCE) and Hypertension Diagnostics (OTCMKTS:HDII) are both medical companies, but which is the superior business? We will contrast the two companies based on the strength of their risk, valuation, institutional ownership, earnings, dividends, profitability and analyst recommendations.

Analyst Recommendations

This is a breakdown of recent ratings for NeuroPace and Hypertension Diagnostics, as provided by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
NeuroPace	1	1	4	2	2.88
Hypertension Diagnostics	0	0	0	0	0.00

NeuroPace presently has a consensus target price of $18.83, indicating a potential upside of 15.12%. Given NeuroPace’s stronger consensus rating and higher possible upside, research analysts plainly believe NeuroPace is more favorable than Hypertension Diagnostics.

Insider & Institutional Ownership

78.8% of NeuroPace shares are held by institutional investors. 20.5% of NeuroPace shares are held by company insiders. Comparatively, 40.0% of Hypertension Diagnostics shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Profitability

This table compares NeuroPace and Hypertension Diagnostics’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
NeuroPace	-21.67%	-108.20%	-18.50%
Hypertension Diagnostics	N/A	N/A	N/A

Valuation and Earnings

This table compares NeuroPace and Hypertension Diagnostics”s gross revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
NeuroPace	$99.99 million	5.58	-$21.47 million	($0.65)	-25.17
Hypertension Diagnostics	N/A	N/A	N/A	N/A	N/A

Hypertension Diagnostics has lower revenue, but higher earnings than NeuroPace.

Volatility and Risk

NeuroPace has a beta of 1.88, meaning that its stock price is 88% more volatile than the S&P 500. Comparatively, Hypertension Diagnostics has a beta of -0.23, meaning that its stock price is 123% less volatile than the S&P 500.

Summary

NeuroPace beats Hypertension Diagnostics on 7 of the 11 factors compared between the two stocks.

About NeuroPace

NeuroPace, Inc. operates as a medical device company in the United States. The company develops RNS system, a brain-responsive neuromodulation system that delivers personalized, real-time treatment at the seizure source for treating medically refractory focal epilepsy. It also records continuous brain activity data and enables clinicians to monitor patients in person and remotely. Its RNS System includes RNS neurostimulator, cortical strip and depth leads, and Patient Remote Monitor, as well as other implantable and non-implantable accessories. The company sells its products to hospital facilities for initial RNS system implant procedures and for replacement procedures. NeuroPace, Inc. was incorporated in 1997 and is headquartered in Mountain View, California.

About Hypertension Diagnostics

Hypertension Diagnostics, Inc. designs, develops, manufactures, and markets proprietary noninvasive medical devices that detect subtle changes in the elasticity of arteries in the United States and internationally. It offers CVProfilor, which allows a physician to non-invasively assess the elasticity of small and large arteries, of which small artery elasticity is the earliest and sensitive marker of cardiovascular disease. The company offers CVProfilor DO-2020, which provides a patient's arterial elasticity indices used in the assessment for underlying vascular disease; CVProfilor MD-3000 that offers a sensitive and specific guide to the presence of blood vessel disease; and HD/PulseWave CR-2000 research cardiovascular profiling system, which provides researchers and scientists with a non-invasive means to assess arterial elasticity in support of human research in various areas. Its products collect 30 seconds of blood pressure waveform data, perform an analysis of the digitized blood pressure waveforms, and generate a CVProfile report that contains information on blood pressure, heart rate, pulse pressure, body surface area, body mass index, and C1-large and C2-small artery elasticity indices. The company sells its products to primary care physicians, cardiologists, health care professionals, trained medical personnel, research investigators at academic medical research centers, government institutes, cardiovascular specialists, and pharmaceutical firms. It markets its products through a representative organization in the United States. Hypertension Diagnostics, Inc. was founded in 1988 and is based in Richmond Hill, Canada.